» Articles » PMID: 25295224

Texaphyrins and Water-soluble Zinc(II) Ionophores: Development, Mechanism of Anticancer Activity, and Synergistic Effects

Overview
Publisher De Gruyter
Date 2014 Oct 9
PMID 25295224
Authors
Affiliations
Soon will be listed here.
Abstract

Texaphyrins, first prepared by Sessler and coworkers in the 1980s, represent early examples of expanded porphyrins. This class of pentaaza, oligopyrrolic macrocycles demonstrates excellent tumor localization and metal-chelating properties. In biological milieus, texaphyrins act as redox mediators and are able to produce reactive oxygen species. Furthermore, texaphyrins have been shown to upregulate zinc , an important feature that inspired us to develop new zinc ionophores that might allow the same function to be elicited but via a simpler chemical means. In this review, the basic properties of texaphyrins and the zinc ionophores they helped spawn will be discussed in the cadre of developing an understanding that could lead to the preparation of new, redox-active anticancer agents.

References
1.
Mehta M, Shapiro W, Glantz M, Patchell R, Weitzner M, Meyers C . Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol. 2002; 20(16):3445-53. DOI: 10.1200/JCO.2002.07.500. View

2.
Feng P, Li T, Guan Z, Franklin R, Costello L . Effect of zinc on prostatic tumorigenicity in nude mice. Ann N Y Acad Sci. 2004; 1010:316-20. DOI: 10.1196/annals.1299.056. View

3.
Young S, Qing F, Harriman A, Sessler J, Dow W, Mody T . Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci U S A. 1996; 93(13):6610-5. PMC: 39073. DOI: 10.1073/pnas.93.13.6610. View

4.
Vallee B . Introduction to metallothionein. Methods Enzymol. 1991; 205:3-7. DOI: 10.1016/0076-6879(91)05077-9. View

5.
Carde P, Timmerman R, Mehta M, Koprowski C, Ford J, Tishler R . Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol. 2001; 19(7):2074-83. DOI: 10.1200/JCO.2001.19.7.2074. View